These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 12223074)

  • 1. Gene targets of antisense therapies in breast cancer.
    Yang DC; Elliott RL; Head JF
    Expert Opin Ther Targets; 2002 Jun; 6(3):375-85. PubMed ID: 12223074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression.
    Li Z; Xia W; Fang B; Yan DH
    Cancer Lett; 2001 Dec; 174(2):151-8. PubMed ID: 11689290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements of antisense oligonucleotides in treatment of breast cancer.
    Yang SP; Song ST; Song HF
    Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
    Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer.
    Nahta R; Esteva FJ
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):143-9. PubMed ID: 14613035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
    Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
    J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R; Ciardiello F; Tortora G
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element.
    Yan DH
    Biochem Biophys Res Commun; 1998 May; 246(2):353-8. PubMed ID: 9610362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
    Warzocha K; Wotowiec D
    Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.